bearish
Celltrion: Understanding Inflectra's U.S. Challenges
593 Views21 Sep 2018 20:00
Celltrion Inc (068270 KS) 's Inflectra (biosimilar of Remicade marketed in the U.S.) has struggled to gain a foothold in the market since its...
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 12-minute read)
Discussions
(Paid Plans Only)
Kemp Dolliver, CFA
Founder
- Celltrion Placement Is Prelude to Merger: Initiate Pair Trade (Short Celltrion/Long Healthcare)23 Oct 2018
- Samsung BioLogics Update22 Oct 2018
- Celltrion Inc Placement - Shorter Lockup Period Will Be an Overhang for Share Price22 Oct 2018
- Celltrion: Understanding Inflectra's U.S. Challenges21 Sep 2018
- Close Long/Short on Celltrion/Celltrion Healthcare: Market Mood on Placement Is Surprisingly Mild20 Sep 2018
- Another Negative Sign for Celltrion: Remsima Retail Price Is Falling Too Fast Too Much30 Aug 2018
- Celltrion: Manufacturing Risks Remain08 Aug 2018
x